These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16375203)

  • 1. [Influence of orlistat therapy on serum insulin level and morphological and functional parameters of peripheral arterial circulation in obese patients].
    Hajduković Z; Jovelić A; Zivotić-Vanović M; Raden S
    Vojnosanit Pregl; 2005 Nov; 62(11):803-10. PubMed ID: 16375203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
    Tong PC; Lee ZS; Sea MM; Chow CC; Ko GT; Chan WB; So WY; Ma RC; Ozaki R; Woo J; Cockram CS; Chan JC
    Arch Intern Med; 2002 Nov; 162(21):2428-35. PubMed ID: 12437401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
    Derosa G; Mugellini A; Ciccarelli L; Fogari R
    Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
    JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.
    Lindgärde F
    J Intern Med; 2000 Sep; 248(3):245-54. PubMed ID: 10971792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.
    Bloch KV; Salles GF; Muxfeldt ES; Da Rocha Nogueira A
    J Hypertens; 2003 Nov; 21(11):2159-65. PubMed ID: 14597860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
    Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with orlistat reduces cardiovascular risk in obese patients.
    Zavoral JH
    J Hypertens; 1998 Dec; 16(12 Pt 2):2013-7. PubMed ID: 9886891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.